Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03223077 · ClinicalTrials.gov registry record

Mucosal and Microbiota Changes During Acute Campylobacteriosis

A clinical trial of Irritable Bowel Syndrome, sponsored by Mayo Clinic.

Recruiting
Registry status
150
Enrollment target
1
Study location

NCT03223077 is a study of Irritable Bowel Syndrome that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 150 participants, roughly in line with the 141-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target. The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03223077, a study of Irritable Bowel Syndrome, is actively recruiting participants, sponsored by Mayo Clinic.

RECRUITING
Registry status
150 participants
Enrollment target
1
Study location

Study Summary

Gastrointestinal (GI) infection with Campylobacter causes inflammation in the bowel and can change bacteria in the gut. Certain individuals with Campylobacter infection are also known to develop chronic bowel problems such as Irritable Bowel Syndrome (IBS). The researchers are doing this study to understand if changes in gut bacteria and gut mucosal lining during an acute infection can help identify individuals who might be at risk for developing problems in the future.

Conditions Studied

Study Locations (1)

Minnesota

  • Mayo Clinic - Rochester

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2014-10-31
Est. Completion 2026-06

Sponsor

Mayo Clinic

2,844 total trials

What the Registry Record Tells You About NCT03223077

The ClinicalTrials.gov registry entry for NCT03223077 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 141-participant average among 47 other Irritable Bowel Syndrome trials with a reported enrollment target. The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Irritable Bowel Syndrome appearing as the primary indexed condition, and to 0 interventions.

NCT03223077 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.

Frequently Asked Questions

What is clinical trial NCT03223077 about?

NCT03223077 is a clinical study titled "Mucosal and Microbiota Changes During Acute Campylobacteriosis". Gastrointestinal (GI) infection with Campylobacter causes inflammation in the bowel and can change bacteria in the gut. Certain individuals with Campylobacter infection are also known to develop chronic bowel problems such as Irritable Bowel Syndrome (IBS). The researchers are doing this study to un...

What is the current status of trial NCT03223077?

This trial is currently recruiting. The enrollment target is 150 participants. The study started on 2014-10-31. Estimated completion is 2026-06.

What conditions does trial NCT03223077 study?

This clinical trial studies the following conditions: Irritable Bowel Syndrome.

Who is sponsoring clinical trial NCT03223077?

This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03223077 being conducted?

This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Irritable Bowel Syndrome

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.